

Supplementary Table S1. Clinical characteristics of PBMC donors with active CD.

	Sex	Age	Time of onset	Maintenance treatment
P1	Male	16	1 year	Infliximab
P2	Male	23	6 months	Mesalazine
P3	Male	23	1 years	Infliximab
P4	Male	26	10 years	Infliximab, Prednisolone
P5	Male	30	4 years	Infliximab, Mesalazine

CD, Crohn's disease; PBMC, peripheral blood mononuclear cell.